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Abstract
Standard polymerase chain reaction methods often cannot detect drug-resistance mutations in
Plasmodium falciparum infections if the mutation is present in ≤ 20% of the parasites. A heteroduplex
tracking assay was developed that can detect dihydrofolate reductase 164-L mutations in variants
representing 1% of the parasites in an individual host. Using this assay, we confirmed the presence
of the mutation in P. falciparum infections in Malawi.
Drug resistance to sulfadoxine-pyrimethamine (SP) is widespread in Malawi and is conferred
by mutations in dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS).1–4
The combination of five mutations (DHFR-51, -59, and -108, and DHPS-437 and -540) has
been strongly associated with SP failure.5,6 Other mutations, such as DHFR-164, DHPS-581,
and DHPS-613, develop later and sequentially add to SP resistance.7–9 In addition, mutations
in DHFR-164 can confer resistance to pyrimethamine and chlorproguanil.7,10 This mutation
is particularly important because its presence could limit the usefulness of the new artemisinin
combination therapy chlorproguanil-dapsone-artesunate, which is currently under
development.11
Plasmodium falciparum infections are almost always mixtures of genetically distinct
variants12 (Juliano J. J. and others, unpublished data). The DHFR-164 mutations are usually
measured using a conventional polymerase chain reaction (PCR) that cannot detect minority
variants.13–15 In this report, we report a new heteroduplex tracking assay (HTA) for
DHFR-164 that can detect minority variants. We use this method to screen patients and
characterize previously reported mutant DHFR-164 isolates from Malawi.2
Clinical samples from two cohorts in Malawi were evaluated by HTA. First, we screened the
85 pregnant women in labor who came to the Queen Elizabeth Central Hospital in Blantyre
who had originally been tested by real-time PCR.2 Second, we tested 52 samples from an
intermittent preventive therapy (IPTp) trial that took place at rural health clinics in Mpemba
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and Madziabango.16 Among the patients from Mpemba and Madziabango, only samples from
the initial visit were used. Therefore, the women had not received any IPTp at the time of
collection. Informed consent, as approved by the ethics committees of the University of North
Carolina and the Malawi College of Medicine/Ministry of Health, was obtained form all
participants in this research study. The clinical characteristics of the patient samples have been
described previously.2,13,16,17
DNA was extracted from filter paper blood spots or frozen blood using the Qiamp DNA minikit
(Qiagen, Valencia, CA). The method for developing HTAs for the detection of point mutations
in malaria has been previously described, and the differences for the DHFR-164 HTA are noted
below.13 Briefly, wild-type DHFR is amplified at the region of interest. The PCR was carried
out in a 50-μL reaction containing 5 μL of DNA, 1.25 units of HotStar Taq DNA polymerase
(Qiagen), 5 μL of 10× PCR buffer, 1 μL of dNTP mixture (catalog no. U1511; Promega,
Madison, WI), 300 nm forward primer (5′-
ATCATTAACAAAGTTGAAGATCTAATAGTTTTAC-3′), and 500 nM reverse primer (5′-
TCGCTAACAGAAATAATTTGATACTCAT-3′).2 This reaction was amplified by
preheating to 95°C for 15 minutes, followed by 35 cycles of 95°C for 30 seconds, 50°C for 30
seconds, and 72°C for 1 minute. The reaction was completed with a 10-minute hold at 72°C.
The PCR products were cloned into a PCR2.1 TOPO plasmid as described in the protocol of
the Topo TA cloning kit (In-vitrogen, Carlsbad, CA), and mutations were randomly introduced
into the construct at the −3, −1, +1, and +3 nucleotides relative to the single nucleotide
polymorphism using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, LaJolle,
CA).13 Screening of probes, probe construction, and labeling of HTA probes were done per
the methods previously described.13,18 The successful probe had the following mutations: +1
T→G and +3 G→T.
The HTAs were performed by a modification of the method of Ngrenngarmlert and others.
18 An annealing reaction consisting of 8 μL of PCR product (either a control or sample DNA)
was mixed with 1 μL of 10× annealing buffer (1 M NaCl, 100 mM Tris-HCl, pH 7.5, 20 mM
EDTA), 2 μL of 6× loading dye, 0.25 μL of 100 pM forward primer, 0.25 μL of 100 pM reverse
primer, and 0.5 μL of radiolabeled probe in a total volume of 12 μL. All HTA gels included
the following controls: water, a non-template control PCR, and PCRs from wild-type (MR4,
MRA-102G) and mutant (MR4, MRA-176G) DNA stocks. Gels were analyzed as previously
described.13
The sensitivity of the DHFR-164 HTA to detect minority variant drug-resistant parasites was
tested using artificial mixtures of wild-type and mutant genomic P. falciparum DNA.14 These
mixtures were at a final total concentration of 0.1 ng of DNA per microliter and all tests were
done in duplicate. The HTA accurately and reproducibly detected mutant variants comprising
as little as 1% of the total parasite population (Table 1).
Of the 90 patient samples from Blantyre previously genotyped by Alker and others, 85 samples
were available to be re-evaluated.2 The other samples were missing or depleted. Of these, 77
(91%) were successfully genotyped by the DHFR-164 HTA. The DHFR-164 mutant variants
were found in all four samples previously found to have the DNFR-164 mutation by real-time
PCR.2 No other DHFR-164 mutants were found.
All four samples were found to be mixed infections by HTA. The relative amount of
DHFR-164–bearing parasites was determined for each sample by Phosphorimager evaluation
of the gels.13 The samples contained the following amounts of DHFR-164 mutant parasites:
patient 1249 (32.8%, Figure 1, lanes I and J), patient 1367 (89.4%, lanes K and L), patient 1628
(20.6%, lanes M and N), and patient 1238 (11.4%, lanes O and P). The isolate from patient
Juliano et al. Page 2













1367 was originally identified as pure mutant DHFR-164 by real-time PCR.2 Thus, the
DHFR-164 mutation is present only in patients with wild-type parasites.
Parasite DNA from patients 1249 and 1628 were TA-cloned per protocol (Invitrogen). Twenty-
five colonies from each of these samples were screened by colony real-time PCR.2,13 From
both samples, a selection of 3 mutant and 2 wild-type plasmids isolated from these colonies
was then sequenced at the University of North Carolina-Chapel Hill Automated DNA
Sequencing Facility. Sequencing confirmed that the three putative mutant clones were mutant
and that the two putative wild-type clones were wild type. The presence of mutant DHFR-164
was previously confirmed by sequencing in patient 1367.2
The results of the HTAs on the other 73 isolates from Queen Elizabeth Central Hospital were
all pure wild-type. All 45 of the patient samples from Mpemba and Madziabango that were
successfully amplified were also pure wild type at DHFR-164. All of these latter samples were
also genotyped by real-time PCR and found to be wild type by this method. Thus, in total
between the two cohorts, we detected mutant DHFR-164 in 4 (3.3%) of 122 successfully
amplified samples by HTA and real-time PCR.
Mutations at other sites in DHFR (DHFR-51, -59, and -108) are common in Malawi. Among
the malaria and human immunodeficiency virus in pregnancy (MHP) samples evaluated, 63
contained parasites that were genotypically pure mutant at all three other DHFR sites by real-
time PCR, including samples 1458 and 1468 (Figure 1, lanes E–H).1 In addition, there were
10, 6, and 2 MHP samples containing either pure wild-type or mixed genotype parasites at
DHFR-51, -59, and -108, respectively. Because the forward primer of the DHFR-164 HTA
lies between the DHFR-108 and DHFR-164 mutation, the assay is highly specific for the
detected mutation. None of the samples containing other DHFR mutations migrated differently,
or contained additional heteroduplexes compared with the control DNA from 3d7
(genotypically wild type at all three sites).
Thus, this report confirms the presence of the DHFR-164L mutation in Malawi by a second
assay method as well as DNA sequencing. We also demonstrate 100% concordance for the
presence of mutant DHFR-164 between the HTA and real-time PCR assay.
The DHFR-164 mutation remains rare in Africa, but has been documented in Central African
Republic, Kenya, Uganda, the Comoros, Tanzania, and among travelers returning to Sweden
from Africa.14,15,19–23 These observations, together with the data presented here, suggest
that DHFR-164L is a problem in Africa.24 Thus, monitoring for the DHFR-164 mutation
should be continued. The ability of the HTA to detect DHFR-164L–bearing variants
representing ≥ 1% of the parasites in an individual host suggest that the method is more sensitive
than standard PCR methods and should be used if proof of the mutation’s absence is needed.
The presence of this mutation in only one of the two cohorts studied here could serve as an
important lesson. The samples from Mpemba and Madziabango were taken early in pregnancy,
before subjects received SP IPTp. The samples from Queen Elizabeth Central Hospital were
obtained at labor and delivery, after the women had probably received IPTp. This suggests that
the difference might be in part caused by in vivo selection for the DHFR-164L genotype. In
vivo selection of drug resistance mutations has been seen for other dhfr/dhps mutations as well
as in other genes in malaria parasites.25,26 Second, this study and all previous studies of dhfr/
dhps mutations in Malawi used conveniently available samples, not samples that were collected
in a manner representative of the general population. An accurate assessment of the prevalence
of this mutation can only be done with a true population-based survey.
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Dihydrolate reductase (DHFR)–164 heteroduplex tracking assay of malaria isolates from
clinical samples. Lanes A–D, controls (water, non-template control [NTC], wild-type
DHFR-164 DNA, and mutant DHFR-164 DNA, respectively). Each clinical sample is done in
duplicate: Lanes E and F, patient 1458 (0% mutant); lanes G and H, patient 1468 (0% mutant);
lanes I and J, patient 1249 (32.8% mutant); lanes K and L, patient 1367 (89.4% mutant); lanes
M and N, patient 1628 (20.6% mutant); lanes O and P, patient 1238 (11.4% mutant).
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Table 1
Sensitivity of the dihydrofolate reductase–164 heteroduplex tracking assay for minority variant drug-resistant parasites
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